Sinuva (Mometasone Furoate) Patent Expiration, LOE Window & CMS Spending

Sinuva (Mometasone Furoate) by Intersect Ent: FDA Orange Book LOE 2034-11-24, 14 AB generics, $29K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIntersect Ent
FDA Application & PathwayN209310 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-11-24
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors14
2024 CMS Total Public Spend$29K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$29K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel